Mansoor Raza Mirza, MD, discusses treatment outcomes with the use of dostarlimab plus chemotherapy in patients with primary advanced or recurrent endometrial cancer whose disease was mismatch repair deficient/microsatellite instability–high, TP53 mutated, or had no specific molecular profile.
Related Keywords
Copenhagen ,Køavn ,Denmark ,Mansoor Raza Mirza ,Department Of Oncology ,Copenhagen University Hospital ,Onclive Tv ,Publications ,Evaluating Key Clinical Updates In The Realm Of Endometrial Cancer ,
comparemela.com © 2020. All Rights Reserved.